New strategy proposed for designing antibody-based HIV vaccine

Jun 14, 2009

WHAT: Most vaccines that protect against viruses generate infection-fighting proteins called antibodies that either block infection or help eliminate the virus before it can cause disease. Attempts to create a vaccine that induces antibodies that prevent HIV infection or disease, however, have so far been unsuccessful. But several recent studies suggest promising new research directions for the development of an antibody-based HIV vaccine, according to John R. Mascola, M.D., deputy director of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, and colleagues.

These studies demonstrate that, contrary to widespread belief, it is not uncommon for people infected with HIV to naturally make antibodies that can neutralize a variety of HIV strains. These antibodies do not protect people from the virus because they arise years after is established. However, if a could prime the body to make these broadly neutralizing antibodies before exposure to HIV, they could potentially prevent infection or hold the virus at bay until an army of immune cells assembles to limit viral replication.

Based on these findings, Dr. Mascola and colleagues recommend a research strategy that uses naturally occurring, broadly neutralizing anti-HIV antibodies for the ultimate design of an antibody-based HIV vaccine.

Key aspects of this strategy include

  • Obtaining new broadly neutralizing antibodies to HIV to expand the pool available for scientists to study
  • Identifying regions on the surface of HIV that are vulnerable to broadly neutralizing antibodies and determining the atomic-level crystal structure of those regions
  • Understanding how broadly neutralizing antibodies to HIV evolve and persist
  • Clarifying the structural differences between anti-HIV antibodies that do and do not have neutralizing properties
  • Determining what quantity of broadly neutralizing antibodies an HIV vaccine must elicit to be effective
  • Learning how anti-HIV neutralizing antibodies and HIV surface proteins evolve in response to one another in people who eventually produce a powerful neutralizing antibody response to the virus
  • Clarifying how HIV surface proteins are presented to the that produce broadly neutralizing antibodies to HIV
  • Determining what immune-system conditions promote the production of broadly neutralizing anti-HIV antibodies

Source: NIH/National Institute of Allergy and Infectious Diseases (news : web)

Explore further: Latent HIV may lurk in 'quiet' immune cells, research suggests

add to favorites email to friend print save as pdf

Related Stories

Scientists identify genetic link that may neutralize HIV

Sep 04, 2008

Scientists from the Gladstone Institute of Virology and Immunology (GIVI) and the National Institutes of Allergy and Infectious Diseases (NIAID) have identified a gene that may influence the production of antibodies that ...

Exhausted B cells fail to fight HIV

Jul 14, 2008

HIV tires out the cells that produce virus-fighting proteins known as antibodies, according to a human study that will be published online July 14 in the Journal of Experimental Medicine.

Scientists Find Rare, Potent Antibody to HIV-1

Feb 23, 2009

(PhysOrg.com) -- Scientists at Duke University Medical Center have for the first time isolated an important antibody in human serum that could potentially play a key role in the design of an AIDS vaccine. The research appears ...

HIV isolate from Kenya provides clues for vaccine design

Jan 02, 2008

Two simple changes in its outer envelope protein could render the AIDS virus vulnerable to attack by the immune system, according to research from Kenya and the Fred Hutchinson Cancer Research Center published in PLoS Medicine.

Recommended for you

HIV testing yields diagnoses in Kenya but few seek care

Jan 29, 2015

Between December 2009 and February 2011, health workers with the AMPATH Consortium sought to test and counsel every adult resident in the Bunyala subcounty of Kenya for HIV. A study in the journal Lancet HIV reports that the campaign yielded more than 1,300 new positive diagnoses, but few of those new ...

The adaptability of pathogens

Jan 28, 2015

Drug-resistant HIV viruses can spread rapidly. This is the conclusion of a study conducted as part of the SWISS HIV Cohort Study, which is supported by the SNSF. Only the continuous introduction of new drugs can stop the ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.